TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05649163

Intervention type: DRUG
Intervention: Disitamab Vedotin
Description: Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.

Intervention type: DRUG
Intervention: Disitamab Vedotin
Description: Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.

Intervention type: DRUG
Intervention: Disitamab Vedotin
Description: Cohort 1: received a regimen containing Disitamab Vedotin. Cohort 2: received an investigator-selected regimen in addition to Disitamab Vedotin; Treatment options selected by the investigator: no treatment containing Disitamab Vedotin was given, and other systemic antitumor agents (including chemotherapy, such as paclitaxel, docetaxel, irinotecan, and fluorouracil) were selected by the investigator in line with clinical practice. Targeted therapy: such as apatinib, ramucirumab; Combination therapy: ramucirumab + paclitaxel; Immune checkpoint inhibitors such as PD1/PD-L1); Cohort 3: receiving a regimen containing Disitamab Vedotin.
Study: NCT04989049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid 5 MG
Description: folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
Study: NCT05542173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BALI association
Description: BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
Study: NCT05695157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture-TOOL
Description: Suture device for fast and standardized closure of the abdominal fascia
Study: NCT06176833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
Study: NCT05703919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titrated Oxygen
Description: Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oxygen
Description: Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
Study: NCT06021236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based intervention
Description: Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing

Intervention type: OTHER
Group type: OTHER
Intervention: CIED procedure routine care
Description: CIED procedure home care guidance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIED procedure routine care
Description: CIED procedure home care guidance
Study: NCT05542173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
Study: NCT06262581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisleizumab(BGB-A317)
Description: 200mg i.v. q3w
Study: NCT05063396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid free anesthesia
Description: Instead of use of large amount of opioids for intraoperative stress response and postoperative pain controlling, during the whole perioperative period patients received no opioid at all. intravenous local anesthetics and thoracic epidural were used.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Opioid-sparing anesthesia
Description: patients will receive opioid-sparing anesthesia protocol with minimal intraoperative sufentanil, remifentanil and epidural hydromorphone.
Study: NCT05690932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: Single dose of PBI-200 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: Single dose of PBI-200 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: Single dose of PBI-200 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: Single dose of PBI-200 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Capsule
Description: Single dose of PBI-200 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Suspension
Description: Single dose of PBI-200 suspension
Study: NCT06107569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (Promicrobioma)
Description: Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.
Study: NCT06567067

Intervention type: DEVICE
Intervention: Pulsenmore ES home ultrasound
Description: Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched

Intervention type: DEVICE
Intervention: Pulsenmore ES home ultrasound
Description: Fetal Ultrasound scanning using Pulsenmore ES device followed with an interview by a human factoring researched
Study: NCT06565637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience to Improve Disordered Eating
Description: See description under Arms
Study: NCT06091527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga practice
Description: 90-minute group yoga classes twice weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 90-minute group education classes twice weekly for 12 weeks to learn holistic healthcare modules.
Study: NCT05444114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Exercise
Description: Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Exercise
Description: Participants perform a 10 minute mental exercise that is either mindful breathing or listening to a story
Study: NCT04163328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HydroEye®
Description: This is an omega-3 fatty acids supplement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HydroEye®
Description: This is an omega-3 fatty acids supplement.
Study: NCT05967767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Hypoxia Exposure
Description: Hypoxia group were exposed to normobaric hypoxia equal to 3420 m (FiO2: 13.5-13.6 %).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric Normoxia Exposure
Description: Placebo group were exposed to normobaric normoxia equal to 162 m (FiO2: 20.9 %) through wearing the altitude generator mask.
Study: NCT04857879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLA:D program (Good Life with osteoArthritis in Denmark)
Description: GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLA:D program (Good Life with osteoArthritis in Denmark)
Description: GLA:D includes disease-specific education combined with neuromuscular exercises. Control interventions include disease-specific education combined with exercises to optimize movement and strength of the affected knee.
Study: NCT04686968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greenhouse Technique
Description: First, the high-strength sutures were passed through the teared tendon, and then Crimson duvet procedure was performed on the footprint from the articular margin of the humeral head to the apex of the greater tubercle, followed by a lateral row anchor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture Combined With Suture Bridge Technique
Description: A three-line anchor suture method is used as in the greenhouse technique, except that the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
Study: NCT06541691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Description: Enteric-coated aspirin tablet 81 mg, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plain aspirin
Description: Plain aspirin tablet 81 mg, once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid strategy
Description: A hybrid strategy composed from:~* A one-page educational flashcard~* Alerting patients on highly polluted days via text message~* Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days~* Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days~* Encouraging patients to consume citrus fruits during highly polluted days
Study: NCT06341465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just Exercise
Description: Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Schroth exercises are including rotational breathing, correction techniques, positioning, mobilization, and three-dimensional exercises specific to their curvature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping
Description: Kinesiological taping will be applied as a tone enhancer or tone reducer according to the the concave and convex sides of the curve.
Study: NCT04981041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel or Ticagrelor
Description: Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel and NOAC
Study: NCT06320470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Session
Description: The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.
Study: NCT04515186

Intervention type: DRUG
Group type: OTHER
Intervention: Meglumine Antimoniate
Description: Vials of a 5mL solution. Each vial contains 405 mg of Sb5+ corresponding to 8.1% Sb5+ (81 mg/mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miltefosine
Description: 50 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 50 mg capsule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotherapy machine
Description: Localized Current Field radio-frequency generating device
Study: NCT06207279

Intervention type: DIAGNOSTIC_TEST
Intervention: rating
Description: rating scales, test ANT

Intervention type: DIAGNOSTIC_TEST
Intervention: rating
Description: rating scales, test ANT

Intervention type: DIAGNOSTIC_TEST
Intervention: rating
Description: rating scales, test ANT

Intervention type: DIAGNOSTIC_TEST
Intervention: rating
Description: rating scales, test ANT
Study: NCT05288205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: SHP2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: SHP2 inhibitor
Study: NCT05755828

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASCT+CAR-T Cell Infusion
Description: CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy, and autologous stem cells were collected and frozen after mobilization of patient stem cells by granulocyte stimulating factor (10μg/kg/d\*5d). BEAM pretreatment was performed. Autologous stem cells were injected 24 h after pretreatment, and the number of CD34+ cells was \> 2\*106/kg. On the 6th day after transplantation, autologous Anti-CD19 CAR T cells were transfused, and the dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. The patients were given constant intravenous drip/push infusion for 30 minutes.
Study: NCT04403022

Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic Assisted Surgery
Description: da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision
Study: NCT05238701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet
Description: LPM3770164 sustained release tablet will be administrated orally single-dose on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LPM3770164 sustained release tablet simulant
Description: LPM3770164 sustained release tablet simulant will be administrated orally single-dose on day 1
Study: NCT04785651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibial osteotomy with Tranexamic acid
Description: Patients who will be in the treatment arm after randomisation will receive 100ml saline with a dosage of 20 mg/kg tranexamic acid intravenously at induction. An additional administration of tranexamic acid (10 mg/kg in 100ml intravenous saline) will be given as a booster at the end of the surgical procedure.~All the patients will undergo to the same tibial osteotomy procedure.
Study: NCT05369221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReSpace™
Description: All of the subjects will be injected with ReSpace™ hydrogel.
Study: NCT04785651

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tibial osteotomy without Tranexamic acid
Description: Patients in this arm will undergo to the tibial osteotomy procedure as by clinical practice
Study: NCT06455163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eerder Erbij
Description: The intervention (Eerder Erbij, EE) is a person-centred, manual-based intervention consisting of education, information and a support group for persons in the early stage of dementia and their main informal caregiver (e.g. spouse, relative), who receive little or no formal care. The intervention will discuss the effects of dementia, and how to cope and adjust to those effects. It will take place in small group sessions led by a health care professional (e.g. casemanager) and is intended for both the person with dementia and the caregiver. The intervention will be personalised to meet needs, interests and strengths of the dyad by discussing the sessions content at the start of the intervention.
Study: NCT05829746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tubridge
Description: Intracranial stent for wide-necked aneurysms
Study: NCT05168007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WID-RGC20(Cariprazine) 3mg/day
Description: The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(3mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WID-RGC20(Cariprazine) 6mg/day
Description: The initial dose is WID-RGC20(Cariprazine) 1.5mg/day, followed by an up-titration of 1.5mg/day until the target dose(6mg/day) is achieved. The investigational product is administered during the double-blind treatment period(6 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day
Description: The placebo comparator is administered during the double-blind treatment period(6 weeks).
Study: NCT05924035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBOT
Description: HBOT treatment on a multiplace chamber (OXYHeal Hyperbaric Oxygen Chamber), 100% oxygen at 2.0 atmospheres for 90 minutes - on 4 consecutive days within 3 hours of completion of exercise training (as soon as practically possible). This will occur during week 2 of data collection.
Study: NCT05521204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Given PO
Study: NCT05411848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2kcal HP PlantBased
Description: Patients will receive a minimum of 1 bottle per day of either (or both of) 2kcal HP PlantBased and/or 2kcal HP PlantBased MultiFibre Tube Feeds for a minimum of 7 days and a maximum of 28 days. During the 12-month follow-up, patients will have access to the same trial prescription as per the 28-day intervention period.
Study: NCT05355194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Patients will be instructed to inhale while taping the application. The tape will be applied in a vertical direction from just below the navel to the pubic region, another tape will be applied over the initial tape in the horizontal direction with minimal stretch. Another tape will be applied over the lumbosacral region making a V shape. The arms of V shall lie over the lumbar region while the base shall rest over the caudal region. Taping will be maintained for at least 48 hours.~The interventions shall be applied for two consecutive menstrual cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Tilts
Description: Patients will be asked to lie in a supine position with legs bent and toes facing forward. Afterward, they will be instructed to pull their belly inwards while pushing pelvis towards the ceiling and keep hip muscles tightened. This position will be maintained for 5 seconds with 3 sets of 20 repetitions. Pelvic tilts must be performed throughout the menstrual cycle.
Study: NCT04960228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Altruism Video
Description: The video provides three vignettes about a diverse set of people who may be more vulnerable to serious health consequences from COVID-19. In each of the stories, high vaccine uptake of those around these vulnerable individuals serves to protect them. This communicates that getting the COVID-19 vaccine can be done for prosocial reasons and to foster a sense of community, as it provides protection not only to oneself, but also to others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Informational Text
Description: The topics included in the text are how COVID-19 spreads, hygiene, physical distancing, and travel restrictions. Participants will complete three comprehension questions, one after each of the following sections: hygiene, physical distancing, and travel restrictions.
Study: NCT06407089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinertial Group
Description: Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment.
Study: NCT05411510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Densah bur
Description: Surgical treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Densah bur
Description: Surgical treatment
Study: NCT04955106

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SEM Scanner
Description: They will perform 2 sets of 3 measures (1 on sacrum, 1 on the right heel and 1 on the left heel)for each patients
Study: NCT05546333

Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
Study: NCT06274554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Oral fluconazole capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules will be used as a comparator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-23 Therapy
Description: Risankizumab (IL-23) or Ustekinumab (IL-12/23) as standard of care treatment.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IL-23 Therapy
Description: Risankizumab (IL-23) or Ustekinumab (IL-12/23) as standard of care treatment.